Hamza Suria is a business leader with an M.B.A. who served as the CEO of AnaptysBio, Inc. from January 2018 until March 2022. During his time, he played a key role in guiding the company's strategy and operations in the...

Hamza Suria is a business leader with an M.B.A. who served as the CEO of AnaptysBio, Inc. from January 2018 until March 2022. During his time, he played a key role in guiding the company's strategy and operations in the biotechnology sector, particularly focusing on antibody-based therapies and inflammation treatments. His leadership style is straightforward, focused on performance and measurable outcomes. In 2021, his total compensation reached about $4.6 million, reflecting a structure tied closely to the company’s success. Notably, Suria left AnaptysBio after providing an immediate notice to the board; he was entitled to a year of salary continuation and further benefits as part of his separation agreement. Scrutinizing his past actions, Suria showed aggressive insider trading activity, peaking where he sold shares worth around $2.4 million in November 2020, indicating a strategic approach to managing his wealth. Interestingly, he held around 418,864 shares at one point, highlighting a significant financial stake in the company's performance. Although he is no longer with AnaptysBio, his influence during a critical growth stage of the company is evident and continues to shape its trajectory after his departure.